Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia.
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Complex antibody profiling to predict clinical outcome in childhood ADS.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Alemtuzumab benefits hard-to-treat MS patients
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Rituximab and multiple sclerosis.
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
Focal vibration in neurorehabilitation.
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Thrombotic microangiopathy associated with use of interferon-beta.
Use of amiloride and multiple sclerosis: registry-based cohort studies.
New Drugs Online report for idebenone
Pages
« first
‹ previous
…
63
64
65
66
67
68
69
70
71
…
next ›
last »